Filed Pursuant to Rule 424(b)(5)
Registration Number 333-278797
The information in this preliminary prospectus supplement is not
complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the
accompanying prospectus are not offers to sell nor solicitations of offers to buy these securities in any jurisdiction where such offer or sale is not permitted.
Subject to Completion, dated November 4, 2024
PRELIMINARY PROSPECTUS SUPPLEMENT
(To prospectus
dated April 18, 2024)
$1,200,000,000
Xcel Energy Inc.
Common Stock
The forward
sellers referred to below are offering shares of our common stock, par value $2.50 per share. We expect to enter into separate forward sale agreements with each of Barclays Bank PLC and Bank of America, N.A., whom we
refer to in such capacity as the forward purchasers, with respect to an aggregate of shares of our common stock. In connection with these forward sale agreements, the forward purchasers or their affiliates
and/or agents, whom we refer to in such capacity as the forward sellers, at our request, are borrowing from third parties and selling to the underwriters an aggregate of shares of our common stock. If in the
good faith, commercially reasonable judgment of a forward purchaser, it or its affiliate is unable to borrow and deliver for sale on the anticipated closing date a number of shares of our common stock underlying the applicable forward sale
agreement, or it or its affiliate would be unable to borrow, at a stock loan rate not greater than a specified rate, and deliver for sale on the anticipated closing date such number of shares of our common stock, or if certain other conditions to
the applicable forward sellers obligations have not been satisfied, then we will issue and sell directly to the underwriters a number of shares of our common stock equal to the number of shares that such forward seller does not borrow and
deliver.
We will not initially receive any proceeds from the sale of our common stock sold by the forward sellers to the underwriters,
except in certain circumstances described in this prospectus supplement, including the last sentence of the previous paragraph. The forward sale agreements provide for settlement on a settlement date or dates to be specified at our discretion on or
prior to June 30, 2026. If we elect to cash settle all or a portion of a forward sale agreement, we may not receive any proceeds from such election, and we may owe cash to the relevant forward purchaser. If we elect to net share settle all or a
portion of a forward sale agreement, we will not receive any cash proceeds from such election, and we may owe shares of our common stock to the relevant forward purchaser. See Underwriting (Conflicts of Interest)Forward Sale
Agreements for a description of the forward sale agreements.
Our common stock is listed on the Nasdaq Stock Market LLC (the
Nasdaq) under the symbol XEL. The last reported sale price of our common stock on the Nasdaq on November 1, 2024 was $66.69 per share.
Investing in
our common stock involves risks. See Risk Factors on page S-8 of this prospectus supplement and in our periodic reports and other information we file with the
Securities and Exchange Commission (the SEC) for important factors you should consider before investing in our common stock.
The underwriters propose to offer shares of our common stock from time to time for sale in one or more transactions on the Nasdaq, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at
negotiated prices, subject to receipt and acceptance by the underwriters and subject to their right to reject any order in whole or in part. In connection with the sale of shares of our common stock, the underwriters may be deemed to have received
compensation in the form of underwriting discounts. The underwriters may effect such transactions by selling shares of our common stock to or through dealers, and such dealers may receive compensation in the form of discounts, concessions or
commissions from the underwriters and/or purchasers of shares of our common stock for whom they may act as an agent or to whom they may sell as principal. The difference between the price at which the underwriters purchase shares of our common stock
and the price at which the underwriters resell such shares may be deemed underwriting compensation.
The underwriters have agreed to
purchase shares of our common stock from the forward sellers at a price of $ per share. We expect to receive estimated net proceeds from the sale of shares of our common stock, before expenses, of approximately $ (or
approximately $ if the underwriters option to purchase additional shares of our common stock is exercised in full, and we elect to have the forward sellers borrow and deliver such shares to the underwriters as described in detail
below) upon full physical settlement of the forward sale agreements, which we expect to occur on or prior to June 30, 2026. For the purpose of calculating the estimated net proceeds to us, we have assumed that the forward sale agreements are
fully physically settled based on the initial forward sale price of $ per share. The forward sale price is subject to adjustment pursuant to the forward sale agreements, and the actual proceeds, if any, will be calculated as described
in this prospectus supplement.
Although we expect to settle the forward sale agreements entirely by the full physical delivery of shares of
our common stock to the forward purchasers in exchange for cash proceeds, we may elect cash settlement or net share settlement for all or a portion of our obligations under each forward sale agreement. See Underwriting (Conflicts of
Interest)Forward Sale Agreements for a description of the forward sale agreements.
We have granted the underwriters an option
for a period of 30 days from the date of this prospectus supplement to purchase up to an additional $180,000,000 of shares of our common stock at a price of $ per share, subject to certain possible adjustments, to cover sales by the
underwriters in the initial offering of the shares or in the open market of a greater number of shares than the total number set forth above. If such option is exercised, we may, in our sole discretion, enter into additional forward sale agreements
with each of the forward purchasers in respect of the number of shares of our common stock that are subject to the exercise of such option. Unless the context requires otherwise, the term forward sale agreements as used in this
prospectus supplement includes any additional forward sale agreements that we may enter into with a forward purchaser in connection with the exercise by the underwriters of their option. If such option is exercised and we elect not to enter into
additional forward sale agreements, we have agreed to issue and sell directly to the underwriters the number of shares of our common stock that are subject to the exercise of such option. If we enter into additional forward sale agreements, and if
in the good faith, commercially reasonable judgment of a forward purchaser, it or its affiliate is unable to borrow, or is unable to borrow at a stock loan rate no greater than a specified rate, and deliver for sale on the anticipated closing date
for the exercise of such option a number of shares of our common stock underlying such additional forward sale agreement, or if certain other conditions to such forward sellers obligations have not been satisfied, then we will issue and sell
directly to the underwriters a number of shares of our common stock equal to the number of shares of our common stock that such forward seller does not borrow and deliver.
Neither the SEC nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this
prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
The underwriters expect
that the shares of our common stock will be delivered against payment on or about , 2024.
Joint
Book-Running Managers
Prospectus Supplement dated , 2024